ViroGates AS (OCSE:VIRO) ROCE %: -53.84% (As of Mar. 2026)


OCSE:VIRO ViroGates AS OCSE:VIRO
44 GF Score
Price kr10.20
GF Value kr6.80
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS ROCE %?

ViroGates AS OCSE:VIRO 44 ROCE % is -53.84% as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 44/100 and a GF Value™ of kr6.80 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ViroGates AS's annualized ROCE % for the quarter that ended in Mar. 2026 was -53.84%.

ViroGates AS  (OCSE:VIRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ViroGates AS ROCE % Related Terms

ViroGates AS ROCE % Historical Data

* Premium members only.

The historical data trend for ViroGates AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS ROCE % Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.64 -66.21 -65.22 -77.71 -55.16

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.25 -117.67 -107.08 -70.29 -53.84
OCSE:VIRO
44GF Score
ViroGates AS OCSE:VIRO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS ROCE % Calculation

ViroGates AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-10.426/( ( (17.66 - 2.591) + (30.589 - 7.856) )/ 2 )
=-10.426/( (15.069+22.733)/ 2 )
=-10.426/18.901
=-55.16 %

ViroGates AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-11.452/( ( (30.589 - 7.856) + (26.771 - 6.962) )/ 2 )
=-11.452/( ( 22.733 + 19.809 )/ 2 )
=-11.452/21.271
=-53.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -53.84% mean?
ViroGates AS (OCSE:VIRO) has a ROCE % of -53.84% as of Mar. 2026.
Is ViroGates AS's ROCE % too high?
ViroGates AS's current ROCE % is -53.84%. Overall, ViroGates AS has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's ROCE % compare to ABT and SYK?
ViroGates AS's ROCE % of -53.84% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current ROCE % is -53.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.80, compared to a current price of kr10.20 — trading 50% above its estimated fair value. The current ROCE % is -53.84%. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current ROCE % is -53.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr10.20 is trading 50% above its estimated GF Value™ of kr6.80. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • ROCE %: -53.84%
  • GF Value™: kr6.80 vs. price of kr10.20 (50% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for OCSE:VIRO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.20
Price
kr6.80
GF Value